Ten years ago, at 43 years old, Jennifer was diagnosed with multiple myeloma during an annual routine physical. She was an active, healthy young mother with no symptoms of cancer.  

She has since undergone a stem cell transplant and now receives medication and labs every 3 months. Jennifer is still being treated by Dr. Anderson, who she claims saved her life and the lives of her four daughters. 

Jennifer chose to be treated at Dana-Farber because of its excellent reputation. She also likes that her team solely focuses on multiple myeloma and has several experts in the field. 

In her spare time, Jennifer loves to exercise, either going on walks or bike rides, take vacation, and spend time with her family. 

She is supported at home by her husband, Glenn; her 21-year-old daughter, Danielle, and her 13-year-old identical triplets, Rachel, Nicole, and Alexa.

Dr. Anderson serves as chief of the Division of Hematologic Neoplasia, director of the Jerome Lipper Multiple Myeloma Center, and vice chair of the Joint Program in Transfusion Medicine at Dana-Farber.

In his four decades of practice and research, including 32 years at Dana-Farber, Anderson has played a central role in transforming myeloma, a cancer of the bone marrow, from a near immediate death sentence to, in many cases, a chronic, manageable illness.

From the 1970s through the ‘90s, not a single new myeloma drug made it into clinical practice. But during the last decade, Anderson has helped shepherd multiple new drugs from laboratory bench through regulatory approval and to the patient bedside.